Abstract
Insulin glargine with concentration of 100 IU/ml (glargine U100) is at present routinely used in the treatment of type 1 and type 2 diabetes and its advantages over human long-acting NPH insulin had been well described. Recently introduced insulin glargine with a concentration of 300 IU/ml (glargine U300) differs from glargine U100 not only by the possibility of application of higher dose in a lower volume but also by numerous other important characteristics.
Owing to a smaller surface size of the subcutaneous depot, glargine U300 has a slower release into circulation, longer half-life and lower variability of action compared to glargine U100. These features result in a lower rate of especially nocturnal hypoglycaemias.
The aim of this paper is to review pharmacokinetic and pharmacodynamic characteristics of glargine U300. We will also describe the results of clinical trials that compared insulin glargine U300 with glargine U100 and discuss the perspectives of its use in the treatment of diabetes.